Nadia Harbeck

Address Breast Center
Oncological Therapy and Clinical Trials Unit
University of Munich



Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich.

Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany. She is scientific director of the West German Study Group. From 2009-2015, she served on the executive board of the EORTC.

Prof. Harbeck is principal investigator or steering committee member of numerous national and international clinical breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She also has a special interest in eHealth and is co-founder of CANKADO, a digital patient diary.

Professor Harbeck has authored more than 350 papers in peer-reviewed journals (cumulative impact factor > 1800) and is coordinating editor-in-chief of Breast Care. For her clinical translational research, she has received numerous awards, including the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract submitted.

Professor Harbeck has been a EC or SC member for numerous national and international conferences. In 2011, she co-chaired the Third IMPAKT Meeting, and the EORTC-NCI-ASCO Meeting on Molecular Markers. She is a panel member of the St. Gallen Consenus Meeting and other international ESMO-sponsored Consensus Conferences such as that on Breast Cancer in Young Women (BCY) or for Advanced Breast Cancer (ABC Lisbon).

Professor Harbeck has been a member of the ESMO Breast Cancer Faculty Group and of the ESMO Principles Of Clinical Trials and Systemic Therapy Faculty Group since 2015.

ESMO 2017 Congress

"Management of early breast cancer (EBC) is changing towards tumour biology dependent multimodality therapy concepts already at primary diagnosis. The Breast Cancer, Early Stage Track addresses the current challenges for routine interdisciplinary management."

Nadia Harbeck


Nadia Harbeck was the Breast Cancer (early stage) Track Chair of the ESMO 2017 Congress, which took place in Madrid, Spain (8-12 September 2017).

View ESMO 2017 Congress meeting resources